What Would Fundamental Change To Reimbursement Mean For Multinationals? – China Big Pharma Roundup
This article was originally published in PharmAsia News
Executive Summary
Although big pharma continued to show strong growth in China, the pace slowed in the first half of the fiscal year. While many stakeholders are focusing on the recent bribery scandal, perhaps a bigger worry is potential reimbursement reform, which could hurt multinationals where it matters most in China, off-patent products.